Careium AB (CARE) AI Stock Analysis

• Market Cap: kr554.64M
• Dividend Yield: N/A
• Average Volume (3M): 28.79K
• Price to Earnings (P/E): 12.5
• Beta (1Y): 0.28
• Revenue Growth: -1.95%
• EPS Growth: -0.45%
• Country: SE
• Employees: 548
• Sector: Healthcare
• Sector Strength: 45
• Industry: Security & Protection Services
• EPS (TTM): 0.26
• Shares Outstanding: 24,326,214
• 10 Day Avg. Volume: 16,977
• 30 Day Avg. Volume: 28,786
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr30.00
• Price Target Upside: 31.58% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 60 Neutral
• Price Target: kr30.00 ▲(31.58% Upside)

Careium AB's overall stock score reflects a stable financial performance with strong profitability and a solid balance sheet. However, technical analysis indicates bearish momentum, which is a significant risk factor. The stock's valuation is attractive with a low P/E ratio, but the lack of dividend yield slightly diminishes its appeal. The absence of earnings call data and corporate events means these factors do not influence the score.

Careium AB Business Overview & Revenue Model

Company Description

Careium AB (CARE) is a leading provider of innovative solutions in the healthcare technology sector, focusing on creating integrated digital services and products that enhance patient care and streamline healthcare operations. The company specializes in remote monitoring technologies, telehealth services, and personalized health management tools, aiming to empower both healthcare providers and patients through technology-driven solutions. Careium operates primarily in the Nordic region, offering scalable solutions designed to improve health outcomes and optimize resource utilization within the healthcare system.

How the Company Makes Money

Careium AB generates revenue through multiple channels, primarily by providing subscription-based services for its digital health platforms and remote monitoring solutions. The company partners with healthcare providers, municipalities, and organizations to implement its technologies, often through long-term contracts that secure a steady income stream. Key revenue streams include licensing fees for software, subscription fees for ongoing services, and sales of hardware components such as monitoring devices. Additionally, Careium may benefit from partnerships with technology firms and research institutions that enhance its product offerings, thus contributing to its overall earnings.

Careium AB Financial Statement Overview

Summary

Careium AB presents a stable financial profile with strong profitability and a solid balance sheet. While the recent decline in revenue growth is a concern, the company maintains healthy margins and a moderate leverage position. Cash flow generation is stable, though there is potential for improving cash conversion. Overall, Careium AB is well-positioned financially, but focusing on revenue growth and cash flow efficiency could enhance its financial standing further.

Income Statement

Careium AB's income statement shows a mixed performance. The TTM data indicates a decline in revenue growth rate by 3.15%, suggesting a potential slowdown in sales. However, the company maintains a healthy gross profit margin of 43.79% and a net profit margin of 5.30%, indicating efficient cost management and profitability. The EBIT and EBITDA margins are also solid at 8.46% and 16.59%, respectively, reflecting operational efficiency. Despite the recent revenue decline, the company has shown resilience in maintaining strong profitability metrics.

Balance Sheet

The balance sheet of Careium AB reflects a stable financial position with a debt-to-equity ratio of 0.31, indicating moderate leverage and a strong equity base. The return on equity (ROE) stands at 6.69%, which, while positive, suggests room for improvement in generating returns for shareholders. The equity ratio is robust, highlighting a solid capital structure with a significant portion of assets financed by equity. Overall, the balance sheet demonstrates financial stability, though there is potential for enhancing shareholder returns.

Cash Flow

Careium AB's cash flow analysis reveals a mixed picture. The free cash flow growth rate is positive at 2.11%, indicating an improvement in cash generation. However, the operating cash flow to net income ratio of 0.57 suggests that cash generation from operations could be stronger. The free cash flow to net income ratio of 0.27 indicates that a portion of earnings is being converted into free cash flow, but there is room for improvement. Overall, the cash flow position is stable, but enhancing cash conversion efficiency would be beneficial.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	840.10M	870.70M	824.60M	725.10M	587.50M	524.10M
Gross Profit	367.90M	373.70M	340.50M	273.70M	240.30M	217.30M
EBITDA	139.40M	150.60M	137.90M	67.90M	67.90M	71.50M
Net Income	44.50M	58.40M	37.90M	-8.60M	4.70M	18.80M
Balance Sheet
Total Assets	1.04B	1.05B	961.40M	992.10M	1.05B	717.30M
Cash, Cash Equivalents and Short-Term Investments	34.10M	31.90M	31.50M	39.90M	142.50M	32.20M
Total Debt	212.40M	196.80M	225.30M	293.50M	292.30M	156.70M
Total Liabilities	368.70M	371.40M	361.90M	425.50M	500.20M	330.80M
Stockholders Equity	674.50M	678.20M	599.50M	566.60M	551.50M	386.50M
Cash Flow
Free Cash Flow	24.20M	36.90M	61.90M	-87.10M	-70.90M	2.70M
Operating Cash Flow	88.20M	92.90M	111.90M	-21.10M	-19.80M	43.80M
Investing Cash Flow	-71.70M	-56.00M	-50.00M	-68.70M	-163.70M	-79.30M
Financing Cash Flow	-14.80M	-39.60M	-69.70M	-15.10M	291.00M	18.60M

Careium AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 22.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CARE, the sentiment is Negative. The current price of 22.8 is below the 20-day moving average (MA) of 23.26, below the 50-day MA of 25.74, and below the 200-day MA of 29.25, indicating a bearish trend. The MACD of -0.69 indicates Negative momentum. The RSI at 37.51 is Neutral, neither overbought nor oversold. The STOCH value of 25.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:CARE.

Careium AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FIRE	78 Outperform	1.08B	24.91	31.28%	3.06%	-4.33%	-17.01%
CNCJO.B	72 Outperform	566.17M	11.31	6.74%	14.46%	5.55%	368.20%
CARE	60 Neutral	kr554.64M	12.46	―	―	-1.95%	-0.45%
TSEC	54 Neutral	139.43M	-2.23	-163.32%	―	2.14%	-205444.83%
LEVEL	47 Neutral	119.39M	-10.64	-3.03%	―	-3.99%	33.17%
IRIS	41 Neutral	31.57M	-0.08	-34.79%	―	-37.37%	23.11%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%